We are privileged to have as our members, the most influential leaders of the Biopharmaceutical industry, whose representatives come together to deepen the level of collaboration and competitiveness of BioPharma operations.
AbbVie - www.abbvie.com
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and capabilities of a long-established pharmaceutical leader to develop and market advanced therapies that address some of the world's most complex and serious diseases. In 2013, AbbVie employed approximately 21,000 people worldwide and markets medicines in more than 170 countries.
Alexion - www.alxn.com
Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with severe and life-threatening rare diseases. Patients with these devastating diseases often have no effective treatment options, and they and their families suffer with little hope.
Their first commercial product is Soliris© (eculizumab), the world's first and only approved terminal complement inhibitor. Today, Soliris is approved in nearly 50 countries as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), and in nearly 40 countries as a treatment for patients with atypical hemolytic uremic syndrome (aHUS). Both PNH and aHUS are life-threatening, ultra-rare diseases that are caused by chronic uncontrolled complement activation.
Amgen - www.amgen.com
Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A leader in biotechnology since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses.
Amgen pioneered the development of novel products based on advances in recombinant DNA and molecular biology, and launched the biotechnology industry's first blockbuster medicines.
AstraZeneca - www.astrazeneca.com
AstraZeneca is a global innovation-driven biopharmaceutical company specialising in the discovery, development, manufacturing and marketing of prescription medicines that make a meaningful difference in healthcare. AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from research, early - and late - stage development to manufacturing and distribution, and the global commercialisation of primary care, specialty care-led and specialty care medicines that transform lives.
Baxter - www.baxter.com
Baxter International Inc. develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. Baxter was responsible for the first commercially manufactured intravenous solutions, the first commercial kidney dialysis machine, the first concentrated clotting factor to treat hemophilia and many other medical breakthroughs.
Bayer - www.bayer.com
Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer's products and services are designed to benefit people and improve the quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer values of Leadership, Integrity, Flexibility and Efficiency - represented by the acronym LIFE - guide their actions as they work to accomplish their mission "Bayer: Science For A Better Life."
Biogen Idec - www.biogenidec.com
Biogen Idec are a global biotechnology company, specializing in discovering, developing, and delivering innovative therapies for the treatment of neurodegenerative, non-malignant hematologic and autoimmune diseases to patients worldwide. Biogen Idec is focused on cutting-edge science and medicines that address unmet patient needs and change the course of these devastating diseases. Founded in 1978, Biogen Idec are the world's oldest independent biotechnology company and take pride in being known for pioneering the development of leading multiple sclerosis therapies.
Bristol-Myers Squibb - www.bms.com
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Bristol-Myers Squibb's medicines are helping millions of patients around the world in their fight against cancer, cardiovascular disease, hepatitis B, HIV/AIDS and rheumatoid arthritis.
Dynavax - www.dynavax.com/
Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. Dynavax has programs partnered with major pharmaceutical companies, including AstraZeneca and GlaxoSmithKline. Dynavax's European subsidiary Rhein Biotech manufactures hepatitis B surface antigen for HEPLISAV. With 20 years in business, Rhein Biotech also provides integrated product development services to enable its partners to bring products to market.
Eisai - www.eisai.com
Eisai Inc. was established in 1995 in Tokyo and began marketing its first product in the United States in 1997. Eisai's areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. Eisai has a global product creation organization that includes U.S.-based R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina. The company's areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs.
Fujifilm - www.fujifilmdiosynth.com
FUJIFILM Diosynth Biotechnologies was formed in April 2011, following the acquisition of the former Diosynth Biotechnologies in Research Triangle Park, NC, USA, and the former Avecia Biologics in Billingham, UK, from Merck & Co Inc. As such the company has a long track record in the development and manufacture of biopharmaceuticals. FUJIFILM Diosynth Biotechnologies combines novel technologies with over 25 years of biopharmaceutical contract manufacturing experience to bring the best in process development and cGMP manufacturing.
Genentech Roche - www.gene.com
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 35 years. At Genentech, they use human genetic information to discover, develop, manufacture and commercialise medicines to treat patients with serious or life-threatening medical conditions. Genentech are among the world's leading biotech companies, with multiple products on the market and a promising development pipeline.
Genzyme - www.genzyme.com
Genzyme is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before.
Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the world's leading biotech companies. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the world's largest pharmaceutical companies, with a shared commitment to improving the lives of patients.
GSK - www.gsk.com
GlaxoSmithKline is one of the world's leading research-based pharmaceutical and healthcare companies. GSK Biopharmaceuticals offers integrated supply chain solutions to support client projects from clinical supply to launch and growth products. Services include rapid scale-up and manufacture of mammalian or microbial cell derived proteins utilising a range of 650L to 20000L bioreactors, the preparation of bulk products, and fill/finish services for sterile liquids and freeze dried drug products. GSK also provides complete process development, analytical and regulatory services to speed technical transfer and regulatory approval.
ImmunoGen - www.immunogen.com
ImmunoGen is focused on changing lives, by using their proven ADC technology to develop novel therapies to provide significant benefits to people with cancer. ImmunoGen is a recognized leader in the field of ADCs. Their technology is used in Roche's Kadcyla (ado-trastuzumab emtansine) - the only ADC with full FDA marketing approval - which is making a difference for patients today. ImmunoGen are also using their proven technology and expertise to develop novel ADCs for their own product pipeline. ImmunoGen continue to invest to maintain our leadership in the emerging, high potential field of ADCs, with 470 issued patents and 570 pending patent applications as of mid-2014.
Ipsen - www.ipsen.ltd.uk
Ipsen, a global specialty-driven pharmaceutical company with total sales exceeding €1.2 billion in 2012. Ipsen's ambition is to become a global leader in the treatment of targeted debilitating diseases with a development strategy supported by three franchises: neurology, endocrinology and uro-oncology. Moreover, the Group has an active policy of partnerships. Research and Development is focused on innovative patient-driven programmes in the areas of peptides and toxins. In 2012, R&D expenditure totalled more than €250 million, greater than 20% of Group sales. The Group has a total worldwide staff of close to 4,900 employees.
Janssen - www.janssenbiotech.com
Janssen Biotech, Inc. has been built on a rich legacy of "firsts" pursuing innovative solutions in the therapeutic areas of immunology, oncology, and nephrology. With the same unwavering passion for new challenges, Janssen Biotech is dedicated in delivering solutions for these disease states where unmet needs continue to exist. Rooted in rich scientific collaborations and community-based relationships, Janssen Biotech has access to some of the top minds in science today. Janssen Biotech, Inc is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Lilly - www.lilly.com
Lilly is a global health care leader that unites caring with discovery to make life better for people
around the world. Founded in 1876, for more than a century, Lilly has stayed true to a core set of values - excellence, integrity, and respect for people that guide them in all they do: discovering medicines that meet real needs, improving the understanding and management of disease, and giving back to communities through philanthropy and volunteerism.
Lonza - www.lonza.com
Lonza is one of the world's leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. Lonza harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life. Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 10,000 employees worldwide.
Merck - www.msd-uk.com
MSD is a global healthcare leader working to help the world be well. Through our prescription medicines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions.
Merck Millipore - www.merckmillipore.com
Merck Millipore is the Life Science division of Merck KGaA of Germany and offers a broad range of innovative, performance products, services and business relationships that enable their customers' success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the Life Science Tools industry, Merck Millipore serves as a strategic partner to customers and helps advance the promise of Life Science. Headquartered in Billerica, Massachusetts, the division has around 10,000 employees, operations in 68 countries. Merck Millipore is known as EMD Millipore in the U.S. and Canada.
Merck Serono - www.merckserono.com
A unique force in the pharmaceutical industry, Merck Serono combines its complementary expertise in new chemical entities (NCEs) and new biological entities (NBEs) to offer innovative prescription drugs of either origin. With comprehensive skills in all areas from research and development to manufacturing, marketing and sales, the division offers its world-class products in over 150 countries worldwide.
Onyx Pharmaceuticals - www.onyx.com
Based in South San Francisco, California, Onyx Pharmaceuticals is an Amgen subsidiary, engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. Onyx is grounded in three leadership hallmarks that guide how they manage their business and build value for patients and shareholders: innovation, patient-centeredness and stewardship.
Pfizer - www.pfizer.com
Pfizer is a leading research-based biopharmaceutical company. Pfizer apply science and their global resources to deliver innovative therapies that extend and significantly improve lives. Pfizer make medicines and vaccines that help people when they are sick and prevent them from getting sick in the first place, as well as some of the world's best-known consumer healthcare brands. Pfizer also collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. For more than 150 years, Pfizer has worked to make a difference.
Regeneron - www.regeneron.com
Known for its scientific and operational excellence, Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, allergic asthma, and atopic dermatitis.
Novavax - www.novavax.com
Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
Roche - www.roche.com
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
Samsung - www.samsung.com
Samsung works to provide the latest technologies delivered by innovative medical devices. Samsung is continuously presenting new products that predict the demands of tomorrow and thus is leading the global digital market.
Sanofi - www.sanofi.com
Sanofi, a global integrated healthcare leader discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme.
Shire - www.shire.com
Shire enables people with life-altering conditions to lead better lives.
Their strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
They focus on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine and are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.
Takeda - www.takeda.com
Takeda is a research-based global pharmaceutical company. As the largest pharmaceutical company in Japan and one of the global leaders of the industry. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation and oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.
UCB - www.ucb.com
UCB aspires to be the patient-centric global biopharmaceutical leader transforming the lives of people living with severe diseases. UCB's focus is on central nervous system and immunology disorders. A global biopharma focused on severe diseases, they combine biology and chemistry to make major breakthroughs and play to their strengths, partnering with the leaders in the pharmaceutical industry with greater or complementary strengths. UCB has operations in approximately 40 countries.
Click on a dot to see more...
The traditional pharmaceutical companies want to apply the expertise we have gained into their own operations. The biopharma sector, and BPOG in particular, have taken the lead.Roberto Cintron, Janssen's Senior Director Quality Operations
The Biotech landscape is going to change dramatically in the coming years and the work Biophorum is currently doing will have played a major part.Ken Green, Senior Director MS&T, Shire
We see major benefits coming from the biophorum concepts and have invested people accordingly.Pat Alred, General Manager, Janssen
The BPOG community benefits from the continuity that an industry conference simply cannot achieve. The role of the BPOG facilitator ensures that the conversations stay active, this maximizes payback for participation.Tim Tousey, Senior Manager Manufacturing, MedImmune
The way BioPhorum is organized - end-user companies exclusively within the biotech sector - makes it an ideal forum that is able to respond quickly.Ekta Mahajan, Senior Engineer, Pharmaceutical Technical Development Group, Roche Group
Feedback we are getting from the industry is that BPOG is now a recognized and trusted voice in the whole process.Barak Barnoon, Director Process Engineering and Analytics at Pfizer